CHA Biotech said on Friday it will appoint Choi Suk-yoon, former Meritz Securities advisor, as vice chairman and CEO at the upcoming general shareholders’ meeting and board meeting on March 31.
Incoming CHA Biotech CEO Choi Suk-yoon
Choi, a veteran of the investment banking industry with over 40 years of experience, began his career at JP Morgan before holding key positions at Daewoo Securities in Tokyo and London. He later served as the country head of Credit Suisse, Barclays, and RBS in Korea, as well as co-head of Goldman Sachs Korea. After three years of teaching at Seoul National University (SNU) Business School, he became president of the corporate division at Meritz Fire & Marine Insurance and later served as an advisor to Meritz Securities.
CHA Biotech also appointed Han Ki-won as head of global business. Han brings 25 years of experience at Daiwa Securities, where he served as global head of the investment banking division in Tokyo and London, and four years as commissioner of KOTRA's Invest Korea.
To streamline the management of CHA Hollywood Presbyterian Medical Center in Los Angeles, former KPMG partner Kim Chang-wook, who has 35 years of experience as a certified public accountant in New York and Los Angeles, has joined as the head of the local hospital management. CHA Biotech also scouted Park Beon to effectively strengthen its internal organization and affiliate management.
Park has 30 years of experience in Samsung Group’s financial companies, restructuring unit, and the London office, and served as the head of Samsung Futures.
Earlier, CHA Bio Group appointed Park Yoo-han, who served as executive editor of KBS economic news and CEO of KBS Business, as head of strategic planning to drive organizational innovation across the group.